Top

Endocrine

Published in:

01-09-2020 | Thyroid Disease | Original Article

Identification of novel HLA-A0201-restricted T-cell epitopes against thyroid antigens in autoimmune thyroid diseases

Authors: Yun Cai, Xinyu Xu, Zheng Zhang, Ping Wang, Qingfang Hu, Yu Jin, Zhixiao Wang, Xiaoyun Liu, Tao Yang

Published in: Endocrine | Issue 3/2020

Abstract

Purpose

The different mechanisms that trigger the autoimmune attack to the thyroid between Hashimoto’s thyroiditis (HT) and Graves’ disease (GD) are still unclear. The aim of this study was to recognize thyroid antigens specific CD8+ T-cell epitopes and explore the relationship between these epitopes and thyroid autoantibodies, duration and classification in these two diseases.

Methods

Free thiiodothyronine, free tetraiodothyronine, thyroid-stimulating hormone, TgAb, and TPOAb were all measured by immunochemiluminometric assays, while TRAb was tested by radioimmunoassay. HLA class I peptide affinity algorithms were applied to predict candidate thyroid autoantigen peptides that blind to HLA-A*0201. The ELISpot assay was used to detect Tg-, TPO-, and TSHR-specific CD8+ T cells.

Results

We demonstrated that TG-6 was a novel HLA-A*0201-restricted CTL epitope in GD. TG-6, TG-7, TG-10, TG-11, and TPO-6 were immunodominant in GD patients compared with HT patients (TG-6: 38.5 vs. 8%, P = 0.034; TG-7, TG-10, TG-11, and TPO-6: 23.1 vs. 0%, P = 0.034). The immunodominance of TG-6 in GD patients was more evident than healthy controls (HC) (TG-6: 35.8 vs. 0%, P = 0.011), but there was no statistically significant difference between HT patients and HC. Subgroup analyses revealed the T-cell responsiveness to TG-6 was stronger in TgAb-negative HT patients (0 vs. 40%, P = 0.033). However, there was no correlation showed for TPOAb, TRAb, medication and duration in both HT and GD patients.

Conclusions

We report for the first time that both diseases, HT and GD, recognize different antigen-specific CD8-positive T cells. Tg maybe the dominant thyroid autoantigen contributing to breaking tolerance in GD. It could improve our knowledge of autoimmune thyroid diseases pathogenesis as well as offer new therapeutical tools in terms of peptide vaccine therapy.

Available only for authorised users

A. Antonelli, S.M. Ferrari, A. Corrado, A. Di Domenicantonio, P. Fallahi, Autoimmune thyroid disorders. Autoimmun. Rev. 14(2), 174–180 (2015). https://doi.org/10.1016/j.autrev.2014.10.016CrossRefPubMed

H.B. Burch, D.S. Cooper, Management of Graves disease: a review. JAMA 314(23), 2544–2554 (2015). https://doi.org/10.1001/jama.2015.16535CrossRefPubMed

M. Rydzewska, M. Jaromin, I.E. Pasierowska, K. Stozek, A. Bossowski, Role of the T and B lymphocytes in pathogenesis of autoimmune thyroid diseases. Thyroid Res. 11, 2 (2018). https://doi.org/10.1186/s13044-018-0046-9CrossRefPubMedPubMedCentral

G.P. Leese, R.V. Flynn, R.T. Jung, T.M. Macdonald, M.J. Murphy, A.D. Morris, Increasing prevalence and incidence of thyroid disease in Tayside, Scotland: the Thyroid Epidemiology Audit and Research Study (TEARS). Clin. Endocrinol. 68(2), 311–316 (2008). https://doi.org/10.1111/j.1365-2265.2007.03051.xCrossRef

S. De Leo, S.Y. Lee, L.E. Braverman, Hyperthyroidism. Lancet 388(10047), 906–918 (2016). https://doi.org/10.1016/S0140-6736(16)00278-6CrossRefPubMedPubMedCentral

J.A. Franklyn, K. Boelaert, Thyrotoxicosis. Lancet 379(9821), 1155–1166 (2012). https://doi.org/10.1016/S0140-6736(11)60782-4CrossRefPubMed

S.M. McLachlan, B. Rapoport, Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity. Endocr. Rev. 35(1), 59–105 (2014). https://doi.org/10.1210/er.2013-1055CrossRefPubMed

A.M. Ramos-Levi, M. Marazuela, Pathogenesis of thyroid autoimmune disease: the role of cellular mechanisms. Endocrinol. Nutr. 63(8), 421–429 (2016). https://doi.org/10.1016/j.endonu.2016.04.003CrossRefPubMed

H. Mikos, M. Mikos, M. Obara-Moszynska, M. Niedziela, The role of the immune system and cytokines involved in the pathogenesis of autoimmune thyroid disease (AITD). Endokrynol. Pol. 65(2), 150–155 (2014). https://doi.org/10.5603/EP.2014.0021CrossRefPubMed

10.

T.J. Smith, L. Hegedus, Graves’ Disease. N. Engl. J. Med 375(16), 1552–1565 (2016). https://doi.org/10.1056/NEJMra1510030CrossRefPubMed

11.

L. Lamki, V.V. Row, R. Volpe, Cell-mediated immunity in Graves’ disease and in Hashimoto’s \thyroiditis as shown by the demonstration of migration inhibition factor (MIF). J. Clin. Endocrinol. Metab. 36(2), 358–364 (1973). https://doi.org/10.1210/jcem-36-2-358CrossRefPubMed

12.

L.J. Guan, X. Wang, S. Meng, L.F. Shi, W.J. Jiang, L. Xiao, X.H. Shi, J. Xu, J.A. Zhang, Increased IL-21/IL-21R expression and its proinflammatory effects in autoimmune thyroid disease. Cytokine 72(2), 160–165 (2015). https://doi.org/10.1016/j.cyto.2014.11.005CrossRefPubMed

13.

F. Menconi, A. Huber, R. Osman, E. Concepcion, E.M. Jacobson, M. Stefan, C.S. David, Y. Tomer, Tg.2098 is a major human thyroglobulin T-cell epitope. J. Autoimmun. 35(1), 45–51 (2010). https://doi.org/10.1016/j.jaut.2010.01.004CrossRefPubMedPubMedCentral

14.

C.W. Li, F. Menconi, R. Osman, M. Mezei, E.M. Jacobson, E. Concepcion, C.S. David, D.B. Kastrinsky, M. Ohlmeyer, Y. Tomer, Identifying a small molecule blocking antigen presentation in autoimmune thyroiditis. J. Biol. Chem. 291(8), 4079–4090 (2016). https://doi.org/10.1074/jbc.M115.694687CrossRefPubMed

15.

Q. Deng, Y. Luo, C. Chang, H. Wu, Y. Ding, R. Xiao, The emerging epigenetic role of CD8+T cells in autoimmune diseases: a systematic review. Front Immunol. 10, 856 (2019). https://doi.org/10.3389/fimmu.2019.00856CrossRefPubMedPubMedCentral

16.

M. Limbach, M. Saare, L. Tserel, K. Kisand, T. Eglit, S. Sauer, T. Axelsson, A.C. Syvanen, A. Metspalu, L. Milani, P. Peterson, Epigenetic profiling in CD4+ and CD8+ T cells from Graves’ disease patients reveals changes in genes associated with T cell receptor signaling. J. Autoimmun. 67, 46–56 (2016). https://doi.org/10.1016/j.jaut.2015.09.006CrossRefPubMed

17.

Z. Sun, W. Zhong, X. Lu, B. Shi, Y. Zhu, L. Chen, G. Zhang, X. Zhang, Association of Graves’ disease and prevalence of circulating IFN-gamma-producing CD28(-) T cells. J. Clin. Immunol. 28(5), 464–472 (2008). https://doi.org/10.1007/s10875-008-9213-4CrossRefPubMed

18.

M. Ehlers, A. Thiel, C. Bernecker, D. Porwol, C. Papewalis, H.S. Willenberg, S. Schinner, H. Hautzel, W.A. Scherbaum, M. Schott, Evidence of a combined cytotoxic thyroglobulin and thyroperoxidase epitope-specific cellular immunity in Hashimoto’s thyroiditis. J. Clin. Endocrinol. Metab. 97(4), 1347–1354 (2012). https://doi.org/10.1210/jc.2011-2178CrossRefPubMed

19.

S. Allelein, A. Kuebart, M. Haase, T. Dringenberg, C. Schmid, M. Schott, M. Ehlers, Measurement of TSH receptor epitope-specific T cells in Graves’ disease. Horm. Metab. Res. 48(12), 862–864 (2016). https://doi.org/10.1055/s-0042-120846CrossRefPubMed

20.

S. Cote-Bigras, A. Dionne, P. Asselin-Mullen, C. Leblicq, D. Rottembourg, Interferon-gamma ELISPOT detecting reactivity of T cells to TSH receptor peptides in Graves’ disease. Clin. Endocrinol. 80(2), 296–300 (2014). https://doi.org/10.1111/cen.12257CrossRef

21.

K. Parker, M. Bednarek, J. Coligan, Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152(1), 163–175 (1994)PubMed

22.

C. Lundegaard, K. Lamberth, M. Harndahl, S. Buus, O. Lund, M. Nielsen, NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res. 36(Web Server issue), W509–W512 (2008). https://doi.org/10.1093/nar/gkn202CrossRefPubMedPubMedCentral

23.

X. Xu, Y. Gu, L. Bian, Y. Shi, Y. Cai, Y. Chen, H. Chen, L. Qian, X. Wu, K. Xu, R. Mallone, H.W. Davidson, L. Yu, J. She, M. Zhang, T. Yang, Characterization of immune response to novel HLA-A2-restricted epitopes from zinc transporter 8 in type 1 diabetes. Vaccine 34(6), 854–862 (2016). https://doi.org/10.1016/j.vaccine.2015.10.108CrossRefPubMed

24.

R. Mallone, E. Martinuzzi, P. Blancou, G. Novelli, G. Afonso, M. Dolz, G. Bruno, L. Chaillous, L. Chatenoud, J.M. Bach, P. van Endert, CD8+ T-cell responses identify beta-cell autoimmunity in human type 1 diabetes. Diabetes 56(3), 613–621 (2007). https://doi.org/10.2337/db06-1419CrossRefPubMed

25.

J.M. Ellis, V. Henson, R. Slack, J. Ng, R.J. Hartzman, C. Katovich Hurley, Frequencies of HLA-A2 alleles in five U.S. population groups. Predominance Of A*02011 and identification of HLA-A*0231. Hum. Immunol. 61(3), 334–340 (2000). https://doi.org/10.1016/s0198-8859(99)00155-xCrossRefPubMed

26.

A. Di Cerbo, R. Di Paola, C. Menzaghi, V. De Filippis, K. Tahara, D. Corda, L.D. Kohn, Graves’ immunoglobulins activate phospholipase A2 by recognizing specific epitopes on thyrotropin receptor. J. Clin. Endocrinol. Metab. 84(9), 3283–3292 (1999). https://doi.org/10.1210/jcem.84.9.5967CrossRefPubMed

27.

C. Evans, N.G. Morgenthaler, S. Lee, D.H. Llewellyn, R. Clifton-Bligh, R. John, J.H. Lazarus, V.K. Chatterjee, M. Ludgate, Development of a luminescent bioassay for thyroid stimulating antibodies. J. Clin. Endocrinol. Metab. 84(1), 374–377 (1999). https://doi.org/10.1210/jcem.84.1.5532CrossRefPubMed

28.

H.J. Lee, C.W. Li, S.S. Hammerstad, M. Stefan, Y. Tomer, Immunogenetics of autoimmune thyroid diseases: a comprehensive review. J. Autoimmun. 64, 82–90 (2015). https://doi.org/10.1016/j.jaut.2015.07.009CrossRefPubMedPubMedCentral

29.

C.W. Li, R. Osman, F. Menconi, E.S. Concepcion, Y. Tomer, Flexible peptide recognition by HLA-DR triggers specific autoimmune T-cell responses in autoimmune thyroiditis and diabetes. J. Autoimmun. 76, 1–9 (2017). https://doi.org/10.1016/j.jaut.2016.09.007CrossRefPubMed

30.

M. Soliman, E. Kaplan, A. Abdel-Latif, N. Scherberg, L.J. DeGroot, Does thyroidectomy, radioactive iodine therapy, or antithyroid drug treatment alter reactivity of patients’ T cells to epitopes of thyrotropin receptor in autoimmune thyroid diseases? J. Clin. Endocrinol. Metab. 80(8), 2312–2321 (1995). https://doi.org/10.1210/jcem.80.8.7543112CrossRefPubMed

31.

Y. Kawakami, M.E. Fisfalen, L.J. DeGroot, Proliferative responses of peripheral blood mononuclear cells from patients with autoimmune thyroid diseases to synthetic peptide epitopes of human thyroid peroxidase. Autoimmunity 13(1), 17–26 (1992). https://doi.org/10.3109/08916939209014631CrossRefPubMed

32.

M.E. Fisfalen, M. Soliman, Y. Okamoto, K. Soltani, L.J. DeGroot, Proliferative responses of T-cells to thyroid antigens and synthetic thyroid peroxidase peptides in autoimmune thyroid disease. J. Clin. Endocrinol. Metab. 80(5), 1597–1604 (1995). https://doi.org/10.1210/jcem.80.5.7745006CrossRefPubMed

33.

C.M. Dayan, M. Londei, A.E. Corcoran, B. Grubeck-Loebenstein, R.F. James, B. Rapoport, M. Feldmann, Autoantigen recognition by thyroid-infiltrating T cells in Graves disease. Proc. Natl. Acad. Sci. USA 88(16), 7415–7419 (1991). https://doi.org/10.1073/pnas.88.16.7415CrossRefPubMed

34.

S. Quaratino, M. Feldmann, C.M. Dayan, O. Acuto, M. Londei, Human self-reactive T cell clones expressing identical T cell receptor beta chains differ in their ability to recognize a cryptic self-epitope. J. Exp. Med 183(2), 349–358 (1996). https://doi.org/10.1084/jem.183.2.349CrossRefPubMed

35.

E.A. James, M. Pietropaolo, M.J. Mamula, Immune recognition of beta-Cells: neoepitopes as key players in the loss of tolerance. Diabetes 67(6), 1035–1042 (2018). https://doi.org/10.2337/dbi17-0030CrossRefPubMedPubMedCentral

36.

Z. Zhao, J. Ren, C. Dai, C.C. Kannapell, H. Wang, F. Gaskin, S.M. Fu, Nature of T cell epitopes in lupus antigens and HLA-DR determines autoantibody initiation and diversification. Ann. Rheum. Dis. 78(3), 380–390 (2019). https://doi.org/10.1136/annrheumdis-2018-214125CrossRefPubMed

37.

Y. Tomer, Y. Ban, E. Concepcion, G. Barbesino, R. Villanueva, D.A. Greenberg, T.F. Davies, Common and unique susceptibility loci in Graves and Hashimoto diseases: results of whole-genome screening in a data set of 102 multiplex families. Am. J. Hum. Genet. 73(4), 736–747 (2003). https://doi.org/10.1086/378588CrossRefPubMedPubMedCentral

38.

W. Ke, T. Sun, Y. Zhang, L. He, Q. Wu, J. Liu, B. Zha, 25-Hydroxyvitamin D serum level in Hashimoto’s thyroiditis, but not Graves’ disease is relatively deficient. Endocr. J. 64(6), 581–587 (2017). https://doi.org/10.1507/endocrj.EJ16-0547CrossRefPubMed

39.

S.A. Morshed, R. Latif, T.F. Davies, Delineating the autoimmune mechanisms in Graves’ disease. Immunol. Res. 54(1–3), 191–203 (2012). https://doi.org/10.1007/s12026-012-8312-8CrossRefPubMedPubMedCentral

40.

B. Rapoport, S.M. McLachlan, Graves’ hyperthyroidism is antibody-mediated but is predominantly a Th1-type cytokine disease. J. Clin. Endocrinol. Metab. 99(11), 4060–4061 (2014). https://doi.org/10.1210/jc.2014-3011CrossRefPubMedPubMedCentral

41.

M.A. Fernandez-Vina, M. Falco, Y. Sun, P. Stastny, DNA typing for HLA class I alleles: I. Subsets of HLA-A2 and of -A28. Hum. Immunol. 33(3), 163–173 (1992). https://doi.org/10.1016/0198-8859(92)90068-xCrossRefPubMed

42.

H. Park, Y.J. Lee, E.Y. Song, M.H. Park, HLA-A, HLA-B and HLA-DRB1 allele and haplotype frequencies of 10 918 Koreans from bone marrow donor registry in Korea. Int J. Immunogenet. 43(5), 287–296 (2016). https://doi.org/10.1111/iji.12288CrossRefPubMed

43.

Y. Li, H.J. Bao, X. Qiu, Q. Yuan, X. Xu, C. Di, W. Zhang, J. Xu, Z.X. Chen, A study on allele frequencies and mismatching proportion of HLA-A,B,Cw,DRB1 and DQB1 on high-resolution donor-recipient typing in Chinese Han population. Chin. J. Med. Genet. 28(1), 7 (2011)

44.

M. Pan, Z.X. Pan, Q. Fan, S. Wang, X. Wang, C. Shen J, Study on the analysis of high-resolution HLA-A, B and DRB1 alleles from 3238 hematopoietic stem cell donors in Jiangsu Han Chinese. Zhonghua Xue Ye Xue Za Zhi 33(2), 4 (2012)

45.

L. Muixi, M. Carrascal, I. Alvarez, X. Daura, M. Marti, M.P. Armengol, C. Pinilla, J. Abian, R. Pujol-Borrell, D. Jaraquemada, Thyroglobulin peptides associate in vivo to HLA-DR in autoimmune thyroid glands. J. Immunol. 181(1), 795–807 (2008). https://doi.org/10.4049/jimmunol.181.1.795CrossRefPubMed

46.

K. Sakai, S. Shirasawa, N. Ishikawa, K. Ito, H. Tamai, K. Kuma, T. Akamizu, M. Tanimura, K. Furugaki, K. Yamamoto, T. Sasazuki, Identification of susceptibility loci for autoimmune thyroid disease to 5q31-q33 and Hashimoto’s thyroiditis to 8q23-q24 by multipoint affected sib-pair linkage analysis in Japanese. Hum. Mol. Genet 10(13), 1379–1386 (2001). https://doi.org/10.1093/hmg/10.13.1379CrossRefPubMed

47.

Y. Tomer, D.A. Greenberg, E. Concepcion, Y. Ban, T.F. Davies, Thyroglobulin is a thyroid specific gene for the familial autoimmune thyroid diseases. J. Clin. Endocrinol. Metab. 87(1), 404–407 (2002). https://doi.org/10.1210/jcem.87.1.8291CrossRefPubMed

48.

S. Ueda, D. Oryoji, K. Yamamoto, J.Y. Noh, K. Okamura, M. Noda, K. Kashiwase, Y. Kosuga, K. Sekiya, K. Inoue, H. Yamada, A. Oyamada, Y. Nishimura, Y. Yoshikai, K. Ito, T. Sasazuki, Identification of independent susceptible and protective HLA alleles in Japanese autoimmune thyroid disease and their epistasis. J. Clin. Endocrinol. Metab. 99(2), E379–E383 (2014). https://doi.org/10.1210/jc.2013-2841CrossRefPubMed

Title: Identification of novel HLA-A0201-restricted T-cell epitopes against thyroid antigens in autoimmune thyroid diseases
Authors: Yun Cai
Xinyu Xu
Zheng Zhang
Ping Wang
Qingfang Hu
Yu Jin
Zhixiao Wang
Xiaoyun Liu
Tao Yang
Publication date: 01-09-2020
Publisher: Springer US
Keywords: Thyroid Disease
Hashimoto Thyroiditis
Thyroid Disease
Published in: Endocrine / Issue 3/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-020-02264-x

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2020

Nitric oxide and TNF-α are correlates of diabetic retinopathy independent of hs-CRP and HbA1c

Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials

Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis

Diagnosis and management of hypocalcemia

Spironolactone reduces biochemical markers of bone turnover in postmenopausal women with primary aldosteronism

Treating thyroid nodules by radiofrequency: is the delivered energy correlated with the volume reduction rate? A pilot study

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage